These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25812991)

  • 1. Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders.
    Khoshnevis M; Sebag J
    BioDrugs; 2015 Apr; 29(2):103-12. PubMed ID: 25812991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
    Morescalchi F; Gambicorti E; Duse S; Costagliola C; Semeraro F
    Expert Opin Drug Saf; 2016 Sep; 15(9):1267-78. PubMed ID: 27388220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic Vitreolysis for Vitreomacular Traction in Diabetic Retinopathy.
    Rizzo S; Bacherini D
    Dev Ophthalmol; 2017; 60():160-164. PubMed ID: 28427074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocriplasmin for pharmacologic vitreolysis.
    Kuppermann BD
    Retina; 2012 Sep; 32 Suppl 2():S225-8; discussion S228-31. PubMed ID: 22929326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic vitreolysis in diabetic retinopathy.
    El-Asrar AM; Al-Mezain HS
    Curr Pharm Biotechnol; 2011 Mar; 12(3):406-9. PubMed ID: 20939804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
    Shaikh M; Miller JB; Papakostas TD; Husain D
    Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
    Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH
    Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
    Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
    Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
    N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of ocriplasmin as a vitreolytic agent].
    Li L; Du H; Li M; Hui Y
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):155-60. PubMed ID: 25908008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocriplasmin use in a selected case with preserved visual acuity.
    Rossi S; Orrico A; Melillo P; Testa F; Simonelli F; Della Corte M
    BMC Ophthalmol; 2015 Oct; 15():146. PubMed ID: 26511080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
    Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
    Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research update of ocriplasmin for symptomatic vitreomacular adhesion].
    Zhang M; Chen Y
    Zhonghua Yan Ke Za Zhi; 2014 Nov; 50(11):866-70. PubMed ID: 25582211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocriplasmin (Jetrea) for vitreomacular adhesion.
    Med Lett Drugs Ther; 2013 Aug; 55(1422):63-4. PubMed ID: 23917386
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.